Table 3

Subgroup analysis for primary efficacy and safety outcomes

Subgroup	HR	95% CI	P value for interaction
Primary efficacy outcome of ischaemic stroke
All patients	0.57	0.37 to 0.87
Gender			0.025
Male	0.44	0.27 to 0.72
Female	1.33	0.58 to 3.10
Age group			0.56
Age <75	0.58	0.36 to 1.00
Age >75	0.75	0.39 to 1.42
Diabetes			0.85
No	0.56	0.33 to 0.94
Yes	0.61	0.30 to 1.20
Cerebrovascular disease			0.93
No	0.58	0.36 to 0.95
Yes	0.61	0.27 to 1.36
Indication for PCI			0.53
Non-ST elevation ACS	0.64	0.36 to 1.16
STEMI	0.50	0.27 to 0.89
Primary safety outcome of intracranial haemorrhage
All patients	0.65	0.34 to 1.25
Gender			0.88
Male	0.64	0.32 to 1.28
Female	0.74	0.12 to 4.44
Age group			0.027
Age <75	0.42	0.18 to 0.96
Age >75	2.10	0.66 to 6.52
Diabetes			0.50
No	0.81	0.33 to 1.96
Yes	0.52	0.19 to 1.37
Cerebrovascular disease			0.37
No	0.57	0.27 to 1.21
Yes	1.18	0.30 to 4.72
Indication for PCI			0.74
Non-ST elevation ACS	7.19	0.29 to 1.76
STEMI	0.58	0.22 to 1.49

ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, St elevation myocardial infarction.